NAUT
Nautilus Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.63
+27.67%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +4.9%
- EBIT
- +16.3%
- EPS
- +13.5%
- Free cash flow
- +7.9%
- Operating cash flow
- +8.2%
Forward estimates
Based on analyst estimates
- Revenue
- +1392.9%
- EBITDA
- -14.8%
- EPS
- -15.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- +18.5%
- EBIT
- +18.0%
- Net income
- +16.6%
- EPS
- +16.1%
- Free cash flow
- +15.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026